Andrew Kessel
1 min read
In This Article:
-
Regeneron Pharmaceuticals agreed to purchase 23andMe for $256 million in a bankruptcy court auction, the company said Monday.
-
The move allows 23andMe to continue to provide DNA testing services.
-
Regeneron pledged to “prioritize the privacy, security and ethical use of 23andMe’s customer data."
Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.
The transaction will allow 23andMe, which